By Catherine Eckford2024-02-22T16:54:03
Clinical studies of Pfizer’s oral medicine for alopecia areata have demonstrated response rates continued to improve for up to two years.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-29T10:14:00Z
2026-05-22T14:48:00Z
Sponsored by CPhI
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-14T12:32:00
Sponsored by Thermo Fisher Scientific
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2026-06-30T14:00:00 2026-06-30T15:00:00
Sponsored by BioRad
Site powered by Webvision Cloud